Abstract
Breast cancer is a complex and heterogeneous disease, with specific subtypes of tumors associated with different prognosis. Currently, the genomic classification of the different molecular types of breast tumors is a key point in the clinical management of patients, allowing thepersonalization of treatment and avoiding unnecessary actions and side effects efeitos. However, genomic analysi…